Literature DB >> 20360768

Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine.

Maria J W D Vosjan1, Lars R Perk, Gerard W M Visser, Marianne Budde, Paul Jurek, Garry E Kiefer, Guus A M S van Dongen.   

Abstract

The positron emitter zirconium-89 ((89)Zr) has very attractive properties for positron emission tomography (PET) imaging of intact monoclonal antibodies (mAbs) using immuno-PET. This protocol describes the step-by-step procedure for the facile radiolabeling of mAbs or other proteins with (89)Zr using p-isothiocyanatobenzyl-desferrioxamine (Df-Bz-NCS). First, Df-Bz-NCS is coupled to the lysine-NH(2) groups of a mAb at pH 9.0 (pre-modification), followed by purification using gel filtration. Next, the pre-modified mAb is labeled at room temperature by the addition of [(89)Zr]Zr-oxalic acid solution followed by purification using gel filtration. The entire process of pre-modification, radiolabeling and purification steps will take about 2.5 h.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20360768     DOI: 10.1038/nprot.2010.13

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  19 in total

1.  Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET.

Authors:  Iris Verel; Gerard W M Visser; Otto C Boerman; Julliette E M van Eerd; Ron Finn; Ronald Boellaard; Maria J W D Vosjan; Marijke Stigter-van Walsum; Gordon B Snow; Guus A M S van Dongen
Journal:  Cancer Biother Radiopharm       Date:  2003-08       Impact factor: 3.099

Review 2.  The promise of immuno-PET in radioimmunotherapy.

Authors:  Iris Verel; Gerard W M Visser; Guus A van Dongen
Journal:  J Nucl Med       Date:  2005-01       Impact factor: 10.057

Review 3.  Antibodies and antimatter: the resurgence of immuno-PET.

Authors:  Anna M Wu
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

4.  Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography.

Authors:  Lars R Perk; Otto J Visser; M Stigter-van Walsum; Maria J W D Vosjan; Gerard W M Visser; Josée M Zijlstra; Peter C Huijgens; Guus A M S van Dongen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-11       Impact factor: 9.236

Review 5.  Development trends for monoclonal antibody cancer therapeutics.

Authors:  Janice M Reichert; Viia E Valge-Archer
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

6.  Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.

Authors:  Hugo J W L Aerts; Ludwig Dubois; Lars Perk; Peter Vermaelen; Guus A M S van Dongen; Bradly G Wouters; Philippe Lambin
Journal:  J Nucl Med       Date:  2008-12-17       Impact factor: 10.057

7.  Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.

Authors:  Iris Verel; Gerard W M Visser; Ronald Boellaard; Otto C Boerman; Julliette van Eerd; Gordon B Snow; Adriaan A Lammertsma; Guus A M S van Dongen
Journal:  J Nucl Med       Date:  2003-10       Impact factor: 10.057

8.  Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology.

Authors:  Bernard M Tijink; Toon Laeremans; Marianne Budde; Marijke Stigter-van Walsum; Torsten Dreier; Hans J de Haard; C René Leemans; Guus A M S van Dongen
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

9.  In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft.

Authors:  Wouter B Nagengast; Elisabeth G de Vries; Geke A Hospers; Nanno H Mulder; Johan R de Jong; Harry Hollema; Adrienne H Brouwers; Guus A van Dongen; Lars R Perk; Marjolijn N Lub-de Hooge
Journal:  J Nucl Med       Date:  2007-07-13       Impact factor: 10.057

10.  89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.

Authors:  Iris Verel; Gerard W M Visser; Ronald Boellaard; Marijke Stigter-van Walsum; Gordon B Snow; Guus A M S van Dongen
Journal:  J Nucl Med       Date:  2003-08       Impact factor: 10.057

View more
  162 in total

Review 1.  PET tracers based on Zirconium-89.

Authors:  Yin Zhang; Hao Hong; Weibo Cai
Journal:  Curr Radiopharm       Date:  2011-04

2.  Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.

Authors:  Arutselvan Natarajan; Frezghi Habte; Sanjiv S Gambhir
Journal:  Bioconjug Chem       Date:  2012-06-11       Impact factor: 4.774

3.  Synthesis and Evaluation of a Zr-89-Labeled Monoclonal Antibody for Immuno-PET Imaging of Amyloid-β Deposition in the Brain.

Authors:  Jens Fissers; Ann-Marie Waldron; Thomas De Vijlder; Bianca Van Broeck; Darrel J Pemberton; Marc Mercken; Pieter Van Der Veken; Jurgen Joossens; Koen Augustyns; Stefanie Dedeurwaerdere; Sigrid Stroobants; Steven Staelens; Leonie Wyffels
Journal:  Mol Imaging Biol       Date:  2016-08       Impact factor: 3.488

4.  Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.

Authors:  Nerissa Therese Viola-Villegas; Samuel L Rice; Sean Carlin; Xiaohong Wu; Michael J Evans; Kuntal K Sevak; Marija Drobjnak; Govind Ragupathi; Ritsuko Sawada; Wolfgang W Scholz; Philip O Livingston; Jason S Lewis
Journal:  J Nucl Med       Date:  2013-09-12       Impact factor: 10.057

5.  Pharmacokinetics, Biodistribution, and Radiation Dosimetry for 89Zr-Trastuzumab in Patients with Esophagogastric Cancer.

Authors:  Joseph A O'Donoghue; Jason S Lewis; Neeta Pandit-Taskar; Stephen E Fleming; Heiko Schöder; Steven M Larson; Volkan Beylergil; Shutian Ruan; Serge K Lyashchenko; Pat B Zanzonico; Wolfgang A Weber; Jorge A Carrasquillo; Yelena Y Janjigian
Journal:  J Nucl Med       Date:  2017-06-21       Impact factor: 10.057

6.  Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging.

Authors:  Eszter Boros; Jason P Holland; Nathaniel Kenton; Nicholas Rotile; Peter Caravan
Journal:  Chempluschem       Date:  2016-01-25       Impact factor: 2.863

7.  Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.

Authors:  Jorge A Carrasquillo; Bernard M Fine; Neeta Pandit-Taskar; Steven M Larson; Stephen E Fleming; Josef J Fox; Sarah M Cheal; Joseph A O'Donoghue; Shutian Ruan; Govind Ragupathi; Serge K Lyashchenko; John L Humm; Howard I Scher; Mithat Gönen; Simon P Williams; Daniel C Danila; Michael J Morris
Journal:  J Nucl Med       Date:  2019-05-03       Impact factor: 10.057

8.  Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.

Authors:  Mohammad Rashidian; Martin W LaFleur; Vincent L Verschoor; Anushka Dongre; Yun Zhang; Thao H Nguyen; Stephen Kolifrath; Amir R Aref; Christie J Lau; Cloud P Paweletz; Xia Bu; Gordon J Freeman; M Inmaculada Barrasa; Robert A Weinberg; Arlene H Sharpe; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

9.  Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer.

Authors:  Jason S Lewis; Wolfgang A Weber; Christian Lohrmann; Eileen M O'Reilly; Joseph A O'Donoghue; Neeta Pandit-Taskar; Jorge A Carrasquillo; Serge K Lyashchenko; Shutian Ruan; Rebecca Teng; Wolfgang Scholz; Paul W Maffuid
Journal:  Clin Cancer Res       Date:  2019-09-20       Impact factor: 12.531

10.  Inert coupling of IRDye800CW and zirconium-89 to monoclonal antibodies for single- or dual-mode fluorescence and PET imaging.

Authors:  Ruth Cohen; Danielle J Vugts; Marijke Stigter-van Walsum; Gerard W M Visser; Guus A M S van Dongen
Journal:  Nat Protoc       Date:  2013-04-25       Impact factor: 13.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.